**Author details**

Morikuni Tobita and Hiroshi Mizuno\*

\*Address all correspondence to: hmizuno@juntendo.ac.jp

Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine, Japan

### **References**


[8] Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25(11):2739-2749.

**5. Future perspective**

148 Regenerative Medicine and Tissue Engineering

**Author details**

Japan

**References**

143-147.

1997;276(5309):71-74.

medicine. J Cell Physiol 2007;213(2):341-347.

Morikuni Tobita and Hiroshi Mizuno\*

Surg Oncol 2000;19(3):226-234.

\*Address all correspondence to: hmizuno@juntendo.ac.jp

In the past decade, basic research characterizing ASCs shows that these cells have the potential to regenerate tissue defects such as large bone defects, and clinical studies have examined the potential use of ASCs to reconstruct oral and maxillofacial tissue. Although clinical studies have only just begun, the use of ASCs in the clinical setting is extremely promising because ASCs are a readily available, multipotent, and abundant cell type with the capability to undergo robust osteogenesis. However, further studies, including research to determine the mechanism of osteogenic differentiation and studies to evaluate the safety of ASC usage, will be necessary to realize the potential of ASCs in clinical regenerative medicine of the future.

Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine,

[1] Ward BB, Brown SE, Krebsbach PH. Bioengineering strategies for regeneration of craniofacial bone: a review of emerging technologies. Oral Dis 2010;16(8):709-716.

[2] Disa JJ, Cordeiro PG. Mandible reconstruction with microvascular surgery. Semin

[3] Emerick KS, Teknos TN. State-of-the-art mandible reconstruction using revascular‐

[5] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multili‐ neage potential of adult human mesenchymal stem cells. Science 1999;284(5411):

[6] Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science

[7] Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative

ized free-tissue transfer. Expert Rev Anticancer Ther 2007;7(12):1781-1788.

[4] Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9(5):641-650.


[33] Urist MR. Bone: formation by autoinduction. Science 1965;150(3698):893-899.

[20] Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adi‐ pose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13(12):4279-4295.

[21] Gimble JM, Bunnell BA, Chiu ES, Guilak F. Concise review: Adipose-derived stromal vascular fraction cells and stem cells: let's not get lost in translation. Stem Cells

[22] Mizuno H, Zuk PA, Zhu M, Lorenz HP, Benhaim P, Hedrick MH. Myogenic differ‐ entiation by human processed lipoaspirate cells. Plast Reconstr Surg 2002;109(1):

[23] Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int

[24] Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodu‐ latory effect of human adipose tissue-derived adult stem cells: comparison with bone

[25] Hicok KC, Du Laney TV, Zhou YS, Halvorsen YD, Hitt DC, Cooper LF, et al. Human adipose-derived adult stem cells produce osteoid in vivo. Tissue Eng 2004;10(3-4):

[26] Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improve‐ ment of postnatal neovascularization by human adipose tissue-derived stem cells.

[27] Bacou F, el Andalousi RB, Daussin PA, Micallef JP, Levin JM, Chammas M, et al. Transplantation of adipose tissue-derived stromal cells increases mass and functional

[28] Zhang Z. Bone regeneration by stem cell and tissue engineering in oral and maxillo‐

[29] Kolk A, Handschel J, Drescher W, Rothamel D, Kloss F, Blessmann M, et al. Current trends and future perspectives of bone substitute materials - From space holders to innovative biomaterials. J Craniomaxillofac Surg 2012. DOI; 10.1016/j.jcms.

[30] den Boer FC, Wippermann BW, Blokhuis TJ, Patka P, Bakker FC, Haarman HJ. Heal‐ ing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow. J Orthop Res

[31] Kneser U, Schaefer DJ, Polykandriotis E, Horch RE. Tissue engineering of bone: the

[32] Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996;(329):300-309.

reconstructive surgeon's point of view. J Cell Mol Med 2006;10(1):7-19.

capacity of damaged skeletal muscle. Cell Transplant 2004;13(2):103-111.

marrow mesenchymal stem cells. Br J Haematol 2005;129(1):118-129.

2011;29(5):749-754.

150 Regenerative Medicine and Tissue Engineering

2012;2012:461718.

Circulation 2004;110(3):349-355.

facial region. Front Med 2011;5(4):401-413.

199-209.

371-380.

2012.01.002

2003;21(3):521-528.


[60] Mizuno H, Tobita M, Uysal AC. Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells 2012;30(5):804-810.

[48] Terheyden H, Menzel C, Wang H, Springer IN, Rueger DR, Acil Y. Prefabrication of vascularized bone grafts using recombinant human osteogenic protein-1--part 3: dos‐ age of rhOP-1, the use of external and internal scaffolds. Int J Oral Maxillofac Surg

[49] Terheyden H, Knak C, Jepsen S, Palmie S, Rueger DR. Mandibular reconstruction with a prefabricated vascularized bone graft using recombinant human osteogenic protein-1: an experimental study in miniature pigs. Part I: Prefabrication. Int J Oral

[50] Cancedda R, Bianchi G, Derubeis A, Quarto R. Cell therapy for bone disease: a re‐

[51] Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci

[52] Chang SC, Tai CL, Chung HY, Lin TM, Jeng LB. Bone marrow mesenchymal stem cells form ectopic woven bone in vivo through endochondral bone formation. Artif

[53] He Y, Zhang ZY, Zhu HG, Qiu W, Jiang X, Guo W. Experimental study on recon‐ struction of segmental mandible defects using tissue engineered bone combined bone marrow stromal cells with three-dimensional tricalcium phosphate. J Craniofac

[54] Mankani MH, Krebsbach PH, Satomura K, Kuznetsov SA, Hoyt R, Robey PG. Pedi‐ cled bone flap formation using transplanted bone marrow stromal cells. Arch Surg

[55] Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, et al. Repair of large bone defects with the use of autologous bone marrow stromal

[56] Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year out‐

[57] Warnke PH, Springer IN, Wiltfang J, Acil Y, Eufinger H, Wehmoller M, et al. Growth and transplantation of a custom vascularised bone graft in a man. Lancet

[58] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The Interna‐ tional Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):

[59] Levi B, Longaker MT. Concise review: adipose-derived stromal cells for skeletal re‐

come of a pilot clinical study. Tissue Eng 2007;13(5):947-955.

generative medicine. Stem Cells 2011;29(4):576-582.

2004;33(2):164-172.

152 Regenerative Medicine and Tissue Engineering

Maxillofac Surg 2001;30(5):373-379.

2000;113 (Pt 7):1161-1166.

Organs 2009;33(4):301-308.

Surg 2007;18(4):800-805.

2001;136(3):263-270.

2004;364(9436):766-770.

315-317.

cells. N Engl J Med 2001;344(5):385-386.

view of current status. Stem Cells 2003;21(5):610-619.

